Incara Trading Symbol Changed to ICRA RESEARCH TRIANGLE PARK, N.C., Dec. 17 /PRNewswire-FirstCall/ -- Incara Pharmaceuticals Corporation ( http://www.incara.com/ ) announced today that as a result of its recent corporate reorganization, NASDAQ has changed its stock trading symbol to ICRA. In November 2003, Incara completed a corporate reorganization that consisted of the merger of Incara Pharmaceuticals into one of its wholly owned subsidiaries. Incara common stock was converted into common stock of the merged company. The common stock will continue to trade as Incara Pharmaceuticals Corporation on the OTC Bulletin Board with the symbol changed to ICRA, effective today. Incara Pharmaceuticals Corporation is developing a new class of small molecule catalytic antioxidants that destroy oxygen-derived free radicals, believed to be an important contributor to the pathogenesis of many diseases. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurological disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease, also known as ALS) and stroke, and in other non-neurological indications such as cancer radiation therapy, chronic bronchitis and asthma. The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual results might differ materially from those anticipated. These statements and other statements made elsewhere by Incara or its representatives, which are identified or qualified by words such as "intends," "likely," "will," "suggests," "expects," "might," "may," "believe," "could," "should," "would," "anticipates," "plans," or the negative of those terms or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Important factors that could cause results to differ include risks associated with the immediate need to obtain funds for operations, uncertainties of scientific research, clinical trials and product development activities. These and other important risks are described in Incara's reports on Form 10-K, Form 10-Q and Form 8-K and its registration statements filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Incara assumes no obligation to update the information in this release. DATASOURCE: Incara Pharmaceuticals Corporation CONTACT: W. Bennett Love of Incara Pharmaceuticals Corporation, +1-919-558-1907 Web site: http://www.incara.com/

Copyright